BioLife Solutions Signs Multi-Year Supply Agreement with Qkine Limited to Expand its Product Portfolio into the Rapidly Growing Cytokines Market
MWN-AI** Summary
BioLife Solutions, Inc. (NASDAQ: BLFS), a premier developer and supplier of bioproduction tools for cell and gene therapy (CGT), has announced a strategic multi-year supply agreement with Qkine Limited, marking an expansion of its product portfolio into the rapidly growing cytokines market. Under this arrangement, BioLife will distribute specific cytokine and growth factor products manufactured by Qkine, securing exclusive worldwide distribution rights for select Qkine products in the CGT domain, alongside non-exclusive rights to other offerings.
Both companies will collaborate on a process development and validation program, aimed at utilizing BioLife's proprietary CellSeal® Connect vial system for packaging specific Qkine products. This collaboration is anticipated to streamline integration into closed and automated CGT workflows. Roderick de Greef, BioLife's Chairman and CEO, expressed enthusiasm for the partnership, highlighting Qkine's strong reputation and the complementary nature of its products to BioLife's existing cell culture supplements.
The cytokines and growth factors are essential for regulating and stimulating cell growth crucial for the manufacturing of CGT. The global cytokines market is valued at approximately $500 million annually, with projections indicating a growth rate in the mid-teens, potentially reaching $1 billion by 2030 due to expanding development pipelines in CGT.
Dr. Robert Scoffin, CEO of Qkine, emphasized the alignment of both companies’ strengths, suggesting that the partnership will enhance customer value and advance the production of next-generation CGT. This agreement signifies BioLife's commitment to diversifying its offerings in strategically profitable areas of the biotechnology landscape, reinforcing its position as a key player in the bioprocessing sector.
MWN-AI** Analysis
BioLife Solutions, Inc. (NASDAQ: BLFS) has recently announced a strategic multi-year supply agreement with Qkine Limited, aimed at tapping into the burgeoning cytokine market. This partnership not only secures exclusive worldwide distribution rights to specific Qkine products within the cell and gene therapy (CGT) sector but also aligns with BioLife's broader growth strategy to diversify its product offerings.
The global cytokine market is currently valued at around $500 million, with projections suggesting it could reach $1 billion by 2030, fueled by the increasing demand for cell and gene therapies. BioLife's collaboration is well-timed as it places the company in a forward-looking position to capitalize on this anticipated growth. By integrating Qkine's high-purity cytokine and growth factor products, BioLife can enhance its cell culture supplement offerings, catering to a market segment that is both profitable and rapidly expanding.
For investors, this partnership signals a robust opportunity for growth within the bioproduction tools space. BioLife's established reputation in the CGT market combined with Qkine's innovative products can lead to increased revenue streams and fortified customer relationships. Moreover, the collaborative development of Qkine's products using BioLife's proprietary CellSeal® Connect system positions the company advantageously against competitors while streamlining workflow efficiencies for customers.
Investors should consider BioLife Solutions as a potentially resilient long-term investment. With strategic partnerships like the one with Qkine, ongoing innovation in product development, and a growing market landscape for cell and gene therapies, BLFS shares could demonstrate healthy upward momentum. However, potential investors must stay apprised of market fluctuations and regulatory challenges that could influence BioLife's operational landscape.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
BOTHELL, Wash., Feb. 12, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces it has entered into a multi-year supply agreement with Qkine Limited under which BioLife will distribute certain cytokine and growth factor products manufactured by Qkine for use in cell and gene therapy manufacturing.
The agreement provides BioLife with exclusive worldwide distribution rights to specific Qkine products for the CGT market and non-exclusive rights to Qkine products in the CGT market. In addition, the companies intend to collaborate on a process development and validation program to enable Qkine to package certain of its products using BioLife's proprietary CellSeal® Connect vial system, which is designed to be incorporated into closed system and/or automated CGT workflows.
Roderick de Greef, BioLife's Chairman and CEO, commented, "We are pleased to establish this strategic distribution and CellSeal® Connect product development relationship with Qkine, a recognized leader in the fast-growing cytokines market. Qkine's cytokine products are highly complementary to our cell culture supplement offerings and expand the portfolio of solutions we offer our CGT customers. We have specifically identified cytokines along with other biologically active cell culture media components as attractive, fast-growing and profitable adjacent product categories that align with our long-term growth strategy."
Dr. Robert Scoffin, Qkine's CEO, added "We are excited to partner with BioLife, a well-respected leader in the bioprocessing tools market. This collaboration brings together our expertise in cytokine innovation with BioLife's extensive reach and customer relationships in the CGT market. Together, we aim to deliver greater value to customers and help advance the development and manufacture of next?generation cell and gene therapies."
Cytokines and growth factors play a vital role in the manufacturing of cell and gene therapies by regulating and stimulating cell growth, activation and performance. According to third-party market research, the current global cytokines market is estimated at $500 million annually and is projected to grow at a mid-teens compound annual rate, reaching $1 billion by 2030, driven by expanding CGT development pipelines.
About Qkine Limited
With headquarters in Cambridge, England, Qkine Limited is dedicated to advancing stem cell and regenerative medicine research by developing high-purity, bioactive growth factors and cytokines. With a focus on scientific rigour and product excellence, Qkine supports cutting-edge biological research and clinical translation worldwide. For more information, please visit www.qkine.com.
About BioLife Solutions
BioLife Solutions is a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) and broader biopharma markets. Our expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, storage and distribution. For more information, please visit www.biolifesolutions.com or follow BioLife on LinkedIn and X.
Cautions Regarding Forward Looking Statements
Certain statements contained in this press release are not historical facts and may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "plans," "expects," "believes," "anticipates," "designed," "may," "estimate," "guidance," and similar words are intended to identify forward-looking statements. Forward-looking statements are based on our current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. A description of certain of these risks, uncertainties and other matters can be found in filings we make with the U.S. Securities and Exchange Commission, all of which are available at www.sec.gov. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by us. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in its expectations with regard to these forward-looking statements or the occurrence of unanticipated events.
Media & Investor Relations
At the Company
Troy Wichterman
Chief Financial Officer
(425) 402-1400
twichterman@biolifesolutions.com
Investors
Alliance Advisors IR
Jody Cain
(310) 691-7100
jcain@allianceadvisors.com
SOURCE BioLife Solutions, Inc.
FAQ**
How does the multi-year supply agreement between BioLife Solutions Inc. (BLFS) and Qkine Limited enhance BioLife's position in the rapidly growing cytokines market?
What specific cytokine and growth factor products will BioLife Solutions Inc. (BLFS) distribute from Qkine Limited, and how do they complement BioLife's existing offerings?
Can you discuss the expected impact of the collaboration on BioLife Solutions Inc. (BLFS) and Qkine Limited's ability to advance cell and gene therapy manufacturing processes?
Considering the projected growth of the cytokines market to $1 billion by 2030, how does this agreement shape BioLife Solutions Inc. (BLFS) long-term growth strategy?
**MWN-AI FAQ is based on asking OpenAI questions about BioLife Solutions Inc. (NASDAQ: BLFS).
NASDAQ: BLFS
BLFS Trading
-3.41% G/L:
$19.13 Last:
247,112 Volume:
$19.83 Open:
